Abstract
Poor sleep quality was associated with plasma Aβ<sub>42</sub> and Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio, with a stronger effect among individuals with aMCI. A better understanding of the role of sleep in plasma Aβ levels in aMCI patients could lead to effective sleep-based intervention against the risk of Alzheimer's disease.
Introduction
Alzheimer’s Disease (AD) is characterized by the accumulation of Amyloid-β (Aβ) plaques in the brain. Recent neuroscience has highlighted the "glymphatic system," a waste-clearance mechanism that flushes metabolic byproducts like Aβ from the brain primarily during deep sleep. While the link between sleep deprivation and Aβ buildup in cerebrospinal fluid (CSF) is well-documented, CSF collection is invasive and PET imaging is expensive.
This study sought to determine if subjective sleep quality (how a person feels they are sleeping) correlates with plasma Aβ levels—a much more accessible blood-based biomarker. Specifically, the researchers focused on individuals with amnestic Mild Cognitive Impairment (aMCI), a clinical stage where memory loss is present but daily function remains intact, as these individuals are at the highest risk of progressing to Alzheimer’s.
Methods
The study involved a cross-sectional analysis of 305 elderly participants (133 with aMCI and 172 cognitively normal controls) recruited from Cognitive Disorders Clinics and community volunteers in Foshan, China.
- Sleep Assessment: Participants completed the Pittsburgh Sleep Quality Index (PSQI), covering seven domains: quality, latency, duration, efficiency, disturbances, medication use, and daytime dysfunction. Higher scores indicate worse sleep.
- Biomarker Analysis: Plasma levels of Aβ40 and Aβ42 were measured using sandwich enzyme-linked immunosorbent assay (ELISA) techniques. The ratio of Aβ42/Aβ40 was also calculated, as it is often a more sensitive predictor of brain amyloid burden.
- Statistical Modeling: Multivariable linear regression was used to find associations, adjusting for age, gender, APOE ε4 status, BMI, education, and comorbidities.
Key Results
Disparities in Sleep Quality
The aMCI group demonstrated significantly poorer sleep quality across nearly all measured domains compared to the cognitively normal (NC) group. The aMCI group had significantly higher global PSQI scores (8.72 ± 3.87) than the NC group (7.10 ± 3.07, p < 0.001). Specific deficits were noted in sleep latency (the time taken to fall asleep), overall duration, and sleep efficiency.
Correlation with Plasma Biomarkers
The most striking insight was that the link between poor sleep and Aβ levels was not uniform across groups.
- Aβ42 Correlation: In the aMCI group, higher PSQI scores (worse sleep) were positively associated with plasma Aβ42 levels (β = 0.063, p = 0.049). This association was not significant in the cognitively normal group.
- The Aβ42/Aβ40 Ratio: A higher PSQI score was associated with a higher Aβ42/Aβ40 ratio in both groups, but the association was much more robust in the aMCI group (β = 0.076 vs. β = 0.030, p for interaction = 0.023).
These associations remained significant even after adjusting for the APOE ε4 genotype and other lifestyle factors, suggesting sleep is an independent contributor to Aβ levels.
Discussion
The findings suggest that as the brain begins to decline cognitively, it may become more sensitive to the "trash-clearing" failures caused by poor sleep. This study reinforces the growing consensus that blood-based biomarkers can reflect neurodegenerative processes. Because Aβ peptides move dynamically between the brain and periphery, plasma levels can serve as a cost-effective proxy for what is happening behind the blood-brain barrier.
Limitations and Future Work
The authors acknowledge several limitations, including the subjective nature of the PSQI and the cross-sectional design, which cannot establish causation. It remains a "chicken or egg" problem: does poor sleep cause Aβ accumulation, or does Aβ accumulation disrupt the brain's sleep-regulating circuits? Future longitudinal studies should investigate whether improving sleep quality through clinical intervention can slow the progression of aMCI to Alzheimer’s Disease.
Summary updated